| Position | Action |
|---|---|
| AMZN trades above $278 on any strength | Trim 20-25% of existing AMZN position |
| 5 trading days ahead of Aug 12 Core CPI print | Reduce position further |
| AMZN opens below $260 on Aug 13 | Accept exit and re-evaluate |
| AMZN drops to $260-265 on a flush | Deploy dry powder to re-enter |
| AMZN breaks above $284 on >75M share volume | Add-back to position |
Amazon's $3T market cap is not a ceiling but a launchpad, supported by three underappreciated growth vectors (Anthropic $200B+ hidden asset, AWS AI re-acceleration, Medicare pharmacy entry), structural margin expansion to 13.1% operating margin, and a technically confirmed breakout coiling for $295-$305 targets.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 236.25 | bullish |
| close_50_sma | 247.45 | bullish |
| close_10_ema | 260.87 | bullish |
| rsi | 63.20 | neutral |
| macd | 6.83 | bullish |
| macds | 2.47 | bullish |
| macdh | 4.36 | bullish |
| boll | 250.14 | bullish |
| boll_ub | 284.28 | neutral |
| boll_lb | 215.99 | neutral |
| atr | 9.58 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Underweight AMZN: Trim 20-25% into strength, trailing stop at $260, pre-commit reduction before Aug 12 CPI
Underweight AMZN with 20-25% trim into strength above $278, trailing stop at $260, and pre-committed reduction ahead of Aug 12 CPI. Structural thesis (AWS +37%, $143B cash vs $17.3B net debt, Anthropic optionality, ROE 30.56%) justifies maintaining 75-80% core exposure, while tactical setup (forward EPS -17%, Q1 FCF -$18.2B, debt +$57B in 90 days, 5 sessions declining-volume consolidation after 15.3% gap-up) and binary CPI catalyst warrant Underweight over Hold or Sell. Pre-committed execution framework eliminates reactive decision-making under pressure. Key reversal signals: daily close above $290 on volume, flush to $260-265 with RSI 50-55, Q2 normalized EPS re-acceleration from $5.75, or Anthropic funding at $200B+.
When: AMZN above $284 on >75M shares with MACD positive
Then: Add-back to position
The Anthropic stake is a $200B+ hidden free option not embedded in current $2.94T market cap
· concedes: Partially concede: Q1 2026 EPS of $5.75 was inflated by $15.7B one-time gain from security sale — but underlying operating income of $23.85B still supports $20+ forward EPS once normalized for investment cycle; The $10.33 consensus forward EPS estimate may be the trough, not the run-rate; Hormuz/oil spike risk is a legitimate tail risk for logistics margins (though not base case)
AMZN is priced for AI-driven margin expansion at the exact moment when capex is suppressing free cash flow, the balance sheet is being levered aggressively, insider selling is providing real supply, and the technical setup is showing exhaustion after a vertical move.
· concedes: 10b5-1 mechanism is a legal shield, not a panic signal — the mechanism itself is pre-announced and mechanical; If Anthropic IPOs at $400B+ valuation and AI capex monetizes faster than historical precedent, the bull wins; The bear case doesn't require every risk to materialize — it requires only one or two to bite (capex disappointment, FCF compression, multiple de-rating, or macro shock)
→ vs conservative: TTM FCF of $3.2B is not a crisis signal but rather the expected result of strategic AWS-like capex build-out that preceded AWS margin explosion and 10x stock appreciation from 2014-2018
→ vs conservative: Post-breakout 'technical exhaustion' narrative misreads five sessions of declining-volume consolidation after 15.3% gap-up as textbook healthy digestion, not exhaustion
→ vs conservative: Debt surge criticism flawed—$210B total debt with $17B net debt and $143B cash means cheap strategic leverage, not financial distress
→ vs conservative: Anthropic optionality (~$200B stake) completely ignored by conservative framework—free call option on top-tier AI lab not priced into valuation
→ vs conservative: Medicare GLP-1 pharmacy launch represents structural growth driver into $100B TAM being completely dismissed by trim thesis
| vwma | 254.89 | bullish |
Support: 270.73 · 260.87 · 250.14 · 235.5 · 225 | Resistance: 284.28 · 287.2 · 275
AMZN technical analysis shows decisive bullish posture following July 31 breakout (close $235.50 → $271.58, +15.3% on 129M shares). Price at $272.26 trades above all major averages (200 SMA $236.25 +15.2%, 50 SMA $247.45 +10.0%, 10 EMA $260.87 +4.4%). RSI at 63.20 is constructive, MACD at 6.83/2.47 with histogram +4.36 confirms accelerating momentum. VWMA at $254.89 rising steadily supports accumulation thesis. Near-term resistance at $284.28 (Bollinger upper band) and $287.20 intraday high; support at $270.73 session low and critical $260.87 (10 EMA). Recommendation: HOLD existing longs with trailing stop at $260; BUY on pullbacks to $260–$265 zone; avoid chasing above $284.
Market Cap
$2,936.68 B
P/E Ratio (TTM)
21.90x
Forward P/E
26.36x
PEG Ratio
1.46
Price / Book
5.32x
EPS (TTM)
$12.43
Forward EPS
$10.33
Beta (5Y)
1.454
52-Week High
$287.20
52-Week Low
$196.00
50-Day Avg
$247.01
200-Day Avg
$235.35
Revenue (TTM)
$775.7 B
Gross Profit (TTM)
$393.8 B
EBITDA (TTM)
$168.9 B
Net Income (TTM)
$135.3 B
Gross Margin
~50.8%
Operating Margin (TTM)
13.69%
Net Margin (TTM)
17.44%
ROE
30.56%
ROA
6.59%
Total Assets
$916.6 B
Total Debt
$209.9 B
Cash & ST Investments
$143.1 B
Net Debt
$17.3 B
Stockholders' Equity
$441.9 B
Debt / Equity
~47.5%
Current Ratio
1.033
Tangible Book Value
$418.5 B
OCF (TTM est)
~$148 B
FCF (TTM)
$3.2 B
Capex (Q1 2026)
$44.2 B
Capex (TTM est)
~$176 B
Q1 2026 Revenue YoY Growth
+16.6%
Q1 2026 Op Margin
13.1%
Diluted Shares Outstanding
10.903 B
Q1 2026 One-Time Gain
$15.7 B
QoQ Debt Change
+$57 B
Interest Expense YoY Increase
+50%
Q1 2026 Business Purchases
$15.4 B
Strengths
Concerns
AMZN reports TTM revenue of $775.7B with 17.44% net margin and elite 30.56% ROE, anchored by AWS dominance and advertising growth. The company is executing an unprecedented AI infrastructure build with Q1 2026 capex of $44.2B (76.7% YoY increase), funded by $57B in new debt, compressing TTM FCF to just $3.2B. Q1 2026 earnings included a $15.7B non-recurring gain overstating true earnings power; normalized EPS likely closer to $2.50-3.00/quarter. With the stock near 52-week highs at 26.36x forward P/E and elevated 1.45 beta, AMZN is fairly valued for long-term quality but offers limited near-term upside and elevated risk at current levels.